Lapatinib induces p27^Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, et al. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget 2012; 3:1600 - 14; PMID: 23307622
   PubMed Web of Science ®Google Scholar
• Waterhouse BR, Gijsen M, Barber PR, Tullis ID, Vojnovic B, Kong A. Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. Oncotarget 2011; 2:728 - 36; PMID: 21908901
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707 - 12; http://dx.doi.org/10.1126/science.2470152; PMID: 2470152
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005; 7:R436 - 43; http://dx.doi.org/10.1186/bcr1020; PMID: 15987448
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al, Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659 - 72; http://dx.doi.org/10.1056/NEJMoa052306; PMID: 16236737
   PubMed Web of Science ®Google Scholar
• Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21:6255 - 63; http://dx.doi.org/10.1038/sj.onc.1205794; PMID: 12214266
   PubMed Web of Science ®Google Scholar
• Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26:2999 - 3005; http://dx.doi.org/10.1200/JCO.2007.14.0590; PMID: 18458039
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008; 272:296 - 306; http://dx.doi.org/10.1016/j.canlet.2008.07.018; PMID: 18774637
   PubMed Web of Science ®Google Scholar
• Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 2010; 10:188; http://dx.doi.org/10.1186/1471-2407-10-188; PMID: 20459769
   PubMed Web of Science ®Google Scholar
• Belletti B, Baldassarre G. New light on p27(kip1) in breast cancer. Cell Cycle 2012; 11:3701 - 2; http://dx.doi.org/10.4161/cc.21573; PMID: 22895010
   PubMed Web of Science ®Google Scholar
• Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, et al. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle 2012; 11:1468 - 76; http://dx.doi.org/10.4161/cc.19882; PMID: 22441703
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501 - 12; http://dx.doi.org/10.1101/gad.13.12.1501; PMID: 10385618
   PubMed Web of Science ®Google Scholar
• Hengst L, Reed SI. Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998; 227:25 - 41; http://dx.doi.org/10.1007/978-3-642-71941-7_2; PMID: 9479824
   PubMed Web of Science ®Google Scholar
• Nigg EA. Targets of cyclin-dependent protein kinases. Curr Opin Cell Biol 1993; 5:187 - 93; http://dx.doi.org/10.1016/0955-0674(93)90101-U; PMID: 8507490
   PubMed Web of Science ®Google Scholar
• Guan X, Wang Y, Xie R, Chen L, Bai J, Lu J, et al. p27(Kip1) as a prognostic factor in breast cancer: a systematic review and meta-analysis. J Cell Mol Med 2010; 14:944 - 53; http://dx.doi.org/10.1111/j.1582-4934.2009.00730.x; PMID: 19298520
   PubMed Web of Science ®Google Scholar
• Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8:253 - 67; http://dx.doi.org/10.1038/nrc2347; PMID: 18354415
   PubMed Web of Science ®Google Scholar
• Li J, Cho YY, Langfald A, Carper A, Lubet RA, Grubbs CJ, et al. Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways. Cancer Prev Res (Phila) 2011; 4:1190 - 7; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0330; PMID: 21791570
   PubMed Web of Science ®Google Scholar
• Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005; 65:18 - 25; PMID: 15665275
   PubMed Web of Science ®Google Scholar
• Ikeda K, Inoue S. Estrogen receptors and their downstream targets in cancer. Arch Histol Cytol 2004; 67:435 - 42; http://dx.doi.org/10.1679/aohc.67.435; PMID: 15781984
   PubMed Web of Science ®Google Scholar
• Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimato K, Wang Y, et al. CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res 2011; 71:2118 - 28; http://dx.doi.org/10.1158/0008-5472.CAN-10-2426; PMID: 21282336
   PubMed Web of Science ®Google Scholar
• Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001; 142:4120 - 30; http://dx.doi.org/10.1210/en.142.9.4120; PMID: 11517191
   PubMed Web of Science ®Google Scholar
• Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64:423 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-03-2446; PMID: 14729654
   PubMed Web of Science ®Google Scholar
• Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 1998; 26:3505 - 12; http://dx.doi.org/10.1093/nar/26.15.3505; PMID: 9671811
   PubMed Web of Science ®Google Scholar
• Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 2004; 101:1566 - 71; http://dx.doi.org/10.1073/pnas.0308319100; PMID: 14745018
   PubMed Web of Science ®Google Scholar
• Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010; 17:319 - 32; http://dx.doi.org/10.1016/j.ccr.2010.02.030; PMID: 20385358
   PubMed Web of Science ®Google Scholar
• Yan M, Rayoo M, Takano EA, Fox SB, kConFab Investigators. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat 2011; 126:395 - 405; http://dx.doi.org/10.1007/s10549-010-0941-9; PMID: 20490651
   PubMed Web of Science ®Google Scholar
• Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008; 14:5228 - 35; http://dx.doi.org/10.1158/1078-0432.CCR-07-4528; PMID: 18698041
   PubMed Web of Science ®Google Scholar
• Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, et al. ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res 2012; 14:R148; http://dx.doi.org/10.1186/bcr3358; PMID: 23158001
   PubMedGoogle Scholar
• Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, et al. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 2012; 18:5911 - 23; http://dx.doi.org/10.1158/1078-0432.CCR-12-1257; PMID: 22896656
   PubMed Web of Science ®Google Scholar
• Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 2000; 97:9042 - 6; http://dx.doi.org/10.1073/pnas.160016897; PMID: 10908655
   PubMed Web of Science ®Google Scholar
• D’Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, et al. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 2010; 123:387 - 96; http://dx.doi.org/10.1007/s10549-009-0649-x; PMID: 19946741
   PubMed Web of Science ®Google Scholar
• Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007; 6:1629 - 40; http://dx.doi.org/10.1158/1535-7163.MCT-05-0399; PMID: 17513611
   PubMed Web of Science ®Google Scholar
• Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000; 20:9138 - 48; http://dx.doi.org/10.1128/MCB.20.24.9138-9148.2000; PMID: 11094066
   PubMed Web of Science ®Google Scholar
• Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL, et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res 2005; 3:163 - 9; http://dx.doi.org/10.1158/1541-7786.MCR-04-0163; PMID: 15798096
   PubMed Web of Science ®Google Scholar
• Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183:10 - 7; http://dx.doi.org/10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; PMID: 10699961
   PubMed Web of Science ®Google Scholar
• Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997; 16:5334 - 44; http://dx.doi.org/10.1093/emboj/16.17.5334; PMID: 9311993
   PubMed Web of Science ®Google Scholar
• DeSalle LM, Pagano M. Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett 2001; 490:179 - 89; http://dx.doi.org/10.1016/S0014-5793(01)02121-4; PMID: 11223033
   PubMed Web of Science ®Google Scholar
• Deng X, Ewton DZ, Mercer SE, Friedman E. Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation. J Biol Chem 2005; 280:4894 - 905; http://dx.doi.org/10.1074/jbc.M411894200; PMID: 15546868
   PubMed Web of Science ®Google Scholar
• Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. J Biol Chem 2004; 279:22498 - 504; http://dx.doi.org/10.1074/jbc.M400479200; PMID: 15010468
   PubMed Web of Science ®Google Scholar
• Dey P, Jonsson P, Hartman J, Williams C, Ström A, Gustafsson JA. Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 2012; 26:1991 - 2003; http://dx.doi.org/10.1210/me.2012.1227; PMID: 23028063
   PubMed Web of Science ®Google Scholar
• Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, et al. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 2005; 34:553 - 66; http://dx.doi.org/10.1677/jme.1.01688; PMID: 15821116
   PubMed Web of Science ®Google Scholar
• Fox EM, Davis RJ, Shupnik MA. ERbeta in breast cancer--onlooker, passive player, or active protector?. Steroids 2008; 73:1039 - 51; http://dx.doi.org/10.1016/j.steroids.2008.04.006; PMID: 18501937
   PubMed Web of Science ®Google Scholar
• Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 2001; 20:1688 - 702; http://dx.doi.org/10.1038/sj.onc.1204245; PMID: 11313917
   PubMed Web of Science ®Google Scholar
• Wang C, Hou X, Mohapatra S, Ma Y, Cress WD, Pledger WJ, et al. Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism. J Biol Chem 2005; 280:12339 - 43; http://dx.doi.org/10.1074/jbc.C400536200; PMID: 15713665
   PubMed Web of Science ®Google Scholar
• Inoue T, Kamiyama J, Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 1999; 274:32309 - 17; http://dx.doi.org/10.1074/jbc.274.45.32309; PMID: 10542271
   PubMed Web of Science ®Google Scholar
• De Vita F, Riccardi M, Malanga D, Scrima M, De Marco C, Viglietto G. PKC-dependent phosphorylation of p27 at T198 contributes to p27 stabilization and cell cycle arrest. Cell Cycle 2012; 11:1583 - 92; http://dx.doi.org/10.4161/cc.20003; PMID: 22441823
   PubMed Web of Science ®Google Scholar
• Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11:1464 - 78; http://dx.doi.org/10.1101/gad.11.11.1464; PMID: 9192873
   PubMed Web of Science ®Google Scholar
• Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9:661 - 4; http://dx.doi.org/10.1016/S0960-9822(99)80290-5; PMID: 10375532
   PubMed Web of Science ®Google Scholar
• Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001; 20:6672 - 82; http://dx.doi.org/10.1093/emboj/20.23.6672; PMID: 11726503
   PubMed Web of Science ®Google Scholar
• Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002; 277:14355 - 8; http://dx.doi.org/10.1074/jbc.C100762200; PMID: 11889117
   PubMed Web of Science ®Google Scholar
• Wada-Hiraike O, Hiraike H, Okinaga H, Imamov O, Barros RP, Morani A, et al. Role of estrogen receptor beta in uterine stroma and epithelium: Insights from estrogen receptor beta-/- mice. Proc Natl Acad Sci U S A 2006; 103:18350 - 5; http://dx.doi.org/10.1073/pnas.0608861103; PMID: 17110437
   PubMed Web of Science ®Google Scholar
• Chen W, Wei F, Xu J, Wang Y, Chen L, Wang J, et al. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. Int J Mol Med 2011; 28:985 - 91; PMID: 21887460
   PubMed Web of Science ®Google Scholar
• Le XF, Pruefer F, Bast RC Jr.. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005; 4:87 - 95; http://dx.doi.org/10.4161/cc.4.1.1360; PMID: 15611642
   PubMed Web of Science ®Google Scholar